^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    dasatinib

    i
    Other names: BMS 354825, BMS-354825, BMS354825
    Company:
    Generic mfg.
    Drug class:
    c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist
    Related drugs:
    10ms
    ➡️ The evolving paradigm of therapy in T-cell ALL by @NitinJainMD at US AML/ALL focus meet @_MDEducation ✅ Bcl2/BclXL inhibitors ✅ CD 7 CAR-Ts ✅ LCK inhibition by Dasatinib/Ponatinib https://t.co/btUp5uOKaW (@jayastuMD)
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1)
    |
    dasatinib • Iclusig (ponatinib)
    10ms
    Great talk by @NitinJainMD on T-ALL ➡️ CAR-T cells being optimized with promising results ➡️ Rationale for inhibition of BCL-2 BCL-xl ➡️ LCK in 40% of T-ALL sensitive to dasatinib/ponatinib. Clinical trial at @MDAndersonNews with chemo-VEN-ponatinib #leusm #ALL @_MDEducation (@FadiHaddad_MD)
    Clinical • CAR T-Cell Therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1)
    |
    dasatinib • Iclusig (ponatinib)
    11ms
    Dasatinib 50 mg daily is as effective and less toxic than 100 mg daily for newly diagnosed CML-CP Georgina Gener-Ricos @FadiHaddad_MD @MDAndersonNews @OncologyAdvance https://t.co/FbCwkDpo11 #leusm #CML (@DrHKantarjian)
    dasatinib
    11ms
    Irinotecan and temozolomide combined with dasatinib and rapamycin for patients with relapsed or refractory neuroblastoma: Results of the prospective randomized RIST trial. #ASCO23 #RIST #NB https://t.co/s0eRomZyqQ (@Satyayadav__)
    Clinical
    |
    dasatinib • temozolomide • irinotecan • sirolimus
    1year
    👉👉 Excited to share that our trial of ponatinib (as LCK inhibitor) + VEN + mini-CVD for R/R T-ALL is now open 👉Joint collaboration MDACC and St Jude @Junjyang @jiyang_yu showed 40% T-ALL overexpress LCK and sensitive to ponatinib/dasatinib (Notably, none had ABL fusion) 1/2 (@NitinJainMD)
    LCK (LCK Proto-Oncogene, Src Family Tyrosine Kinase)
    |
    LCK overexpression
    |
    dasatinib • Iclusig (ponatinib)
    over1year
    Interesting story on FOXA2 & KIT pathway activation driving neuroendocrine prostate cancer @Cancer_Cell. Wonder if we learned anything from phase 3 trial of dasatinib that could be informative? @mishabeltran @aapariciomd @edwinposadasmd https://t.co/6dgbgM1jUG (@NimaSharifiMD)
    FOXA2 (Forkhead Box A2)
    |
    dasatinib
    over1year
    Clonal eosinophilia FIP1L1-PDGFRA= CHIC2 del= imatinib 100 ETV6-PDGFRB = t(5;12)= imatinib 400 ZMYM2-FGFR1= t(8;13)= TKI+AML/ALL induction+allo PCM1-JAK2= t(8;9)= ruxolitinib+allo ETV6-FLT3/ABL1= t(12;13)/t(9;12)= dasatinib+allo Lymphocytic= T-cell clone makes IL5= mepolizumab (@AaronGoodman33)
    ABL1 (ABL proto-oncogene 1) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • JAK2 (Janus kinase 2) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • ETV6 (ETS Variant Transcription Factor 6) • FIP1L1 (Factor Interacting With PAPOLA And CPSF1) • PCM1 (Pericentriolar Material 1) • IL5 (Interleukin 5)
    |
    dasatinib • imatinib • Jakafi (ruxolitinib)
    over1year
    #ESMO22│@drclaireroddie from @uclcancer @UCLH gives her expert opinion on toxicities with #CART and #bispecifics, including potential for dasatinib to manage CRS, and the strong association of HLH with CD22 #CART #mmsm #lymphoma (@lymphomahub)
    CD22 (CD22 Molecule)
    |
    dasatinib
    over1year
    #ESMO22│@drclaireroddie from @uclcancer @UCLH offers her expert opinion on toxicities with #CART and #bispecifics, including potential for dasatinib to manage CRS, and the strong association of HLH with CD22 #CART #mmsm #lymphoma (@MM_Hub)
    CD22 (CD22 Molecule)
    |
    dasatinib
    almost2years
    How does SNAI2 silencing control tumor initiation? Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity 🔗https://t.co/gcicrZursb 🖊️@subhiii_n @sjostrom_martin @travisgerke @loreleimucci @felixfengmd @DrPhilKantoff #PCSM #Dasatinib (@MolOncology)
    SNAI2 (Snail Family Transcriptional Repressor 2)
    |
    dasatinib
    almost2years
    Clinical trial (NCT05268003) investigates combined ponatinib and venetoclax with mini-CVD chemotherapy in pts with R/R T-ALL. Ponatinib (and dasatinib) work by inhibiting LCK enzyme. LCK is over expressed in about 40% T-ALL (no ABL fusions), mostly non-ETP subset @Junjyang (@NitinJainMD)
    Clinical
    |
    LCK (LCK Proto-Oncogene, Src Family Tyrosine Kinase)
    |
    Venclexta (venetoclax) • dasatinib • Iclusig (ponatinib)
    almost2years
    Clonal eosinophilia! FIP1L1-PDGFRA= CHIC2 del= imatinib 100 ETV6-PDGFRB = t(5;12)= imatinib 400 ZMYM2-FGFR1= t(8;13)= TKI+AML/ALL induction+allo PCM1-JAK2= t(8;9)= ruxolitinib+allo ETV6-FLT3/ABL1= t(12;13)/t(9;12)= dasatinib+allo Lymphocytic= T-cell clone makes IL5= mepolizumab (@AaronGoodman33)
    ABL1 (ABL proto-oncogene 1) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • JAK2 (Janus kinase 2) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • ETV6 (ETS Variant Transcription Factor 6) • FIP1L1 (Factor Interacting With PAPOLA And CPSF1) • PCM1 (Pericentriolar Material 1) • IL5 (Interleukin 5)
    |
    dasatinib • imatinib • Jakafi (ruxolitinib)
    over2years
    Phase I study of first line osimertinib + dasatinib in patients with #EGFR NSCLC led by Dr. @chulkimMD now online @FrontOncology. Based on targeting CRIPTO via Src which may mediate EGFR TKI resistance. Small study but 90% had a response with one ongoing. https://t.co/nxx5KpLzkJ (@StephenVLiu)
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    Tagrisso (osimertinib) • dasatinib
    over3years
    #ASH20 #leusm Sasaki: Fascinating differences between Dasatinib v Ponatinib outcomes. Both vulnerable to IKZF1 plus, but Ponatinib overcomes risk of isolated IKZF1del. (@hemedoc)
    IKZF1 (IKAROS Family Zinc Finger 1)
    |
    IKZF1 deletion
    |
    dasatinib • Iclusig (ponatinib)
    over3years
    #ASH20 #leusm Sasaki: IKZF1 deletions known to be risk for poor outcome in Ph+ ALL treated with imatinib or dasatinib. Pre-tx samples from 55 tx with hCVAD/Dasat and 50 tx with hCVAD/Ponat evaluated. IZKF1del found in 60%. (@hemedoc)
    IKZF1 (IKAROS Family Zinc Finger 1)
    |
    IKZF1 deletion
    |
    dasatinib • imatinib
    almost7years
    Phase 1 study bevacizumab+dasatinib with interesting activity in #endometrial cancer @ASCO @NCIResearchCtr #ASCO17 (@CMAnnunziata)
    P1 data
    |
    Avastin (bevacizumab) • dasatinib